Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $28.00 | Outperform | Wolfe Research |
| 12/3/2024 | $23.00 | Equal-Weight | Morgan Stanley |
| 4/22/2024 | Outperform | Exane BNP Paribas | |
| 11/1/2023 | $39.00 → $29.00 | Buy → Hold | Jefferies |
| 9/26/2023 | $33.00 | Overweight | Stephens |
| 9/19/2023 | Market Outperform | CJS Securities | |
| 8/24/2023 | $34.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/9/2022 | $30.00 → $22.00 | Overweight | Morgan Stanley |
Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00
Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00
Exane BNP Paribas initiated coverage of Stevanato Group S.p.A. with a rating of Outperform
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regi
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total revenue. For the second quarter, diluted earnings per share were €0.08 and adjusted diluted earnings per share were €0.09. Adjusted EBITDA margin for the second quarter was 20.8%. The Company is updating its fiscal year 2024 guidan
SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)
-All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th
Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera
The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i
6-K - Stevanato Group S.p.A. (0001849853) (Filer)
SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET. A live event webcast will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solution
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:00 a.m. (GMT), and the Citi 2024 Global Healthcare Conference in Miami on Tuesday, December 3, 2024 at 1:45 p.m. (ET). A live webcast of each event will be ava
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida